Somatic alterations as the basis for resistance to targeted therapies

Brian G. Blair, Alberto Bardelli, Ben Ho Park

Research output: Contribution to journalArticlepeer-review

Abstract

Recent advances in genetics and genomics have revealed new genes and pathways that are somatically altered in human malignancies. This wealth of knowledge has translated into molecularly defined targets for therapy over the past two decades, serving as key examples that translation of laboratory findings can have great impact on the ability to treat patients with cancer. However, given the genetic instability and heterogeneity that are characteristic of all human cancers, drug resistance to virtually all therapies has emerged, posing further and future challenges for clinical oncology. Here we review the history of targeted therapies, including examples of genetically defined cancer targets and their approved therapies. We also discuss resistance mechanisms that have been uncovered, with an emphasis on somatic genetic alterations that lead to these phenotypes.

Original languageEnglish
Pages (from-to)244-254
Number of pages11
JournalJournal of Pathology
Volume232
Issue number2
DOIs
Publication statusPublished - Jan 2014

Keywords

  • cancer
  • drug resistance
  • somatic alterations
  • targeted therapies

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Fingerprint Dive into the research topics of 'Somatic alterations as the basis for resistance to targeted therapies'. Together they form a unique fingerprint.

Cite this